The Gene Therapy in Oncology market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Gene Therapy in Oncology size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Gene Therapy in Oncology market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation

Gene Therapy in Oncology market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Ex Vivo
In Vivo

Market segment by Application, can be divided into
Hospitals
Diagnostics Centers
Research Institutes

Market segment by players, this report covers
Bristol-Myers Squibb
Cold Genesys
Advantagene
Amgen
AstraZeneca
Bio-Path Holdings
CRISPR Therapeutics
Editas Medicine
Geron Corp
Idera Pharmaceuticals
Intellia Therapeutics
Johnson & Johnson
Marsala Biotech
Merck
Mologen AG
Oncolytics Biotech
Oncosec
Oncotelic
Shenzhen SiBiono GeneTech
Sillajen Biotherapeutics
Tocagen
UniQure
Ziopharm Oncology

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)